Earnings
Home›Earnings›Analyst Ratings›Eli Lilly widens lead in GLP-1 market share as Novo No…
Eli Lilly widens lead in GLP-1 market share as Novo Nordisk faces pressure
MarketBeat Ratings says Novo Nordisk’s long term plan is seen as more of a business offset than a premium growth driver, while Eli Lilly holds more than 60% of the GLP-1 market.
Eli Lilly is extending its edge over Novo Nordisk in GLP-1s, with MarketBeat Ratings pointing to patent timing and current market share as the key factors shaping how quickly the gap could narrow.
The outlet says Lilly is positioned to maintain exclusivity longer, and that Novo’s capital markets plan laid out at its September event did not convince investors it could reverse the market momentum. MarketBeat Ratings also characterizes the outlook for Novo as dim relative to Lilly, with competition increasingly expected to erode pricing over time.
MarketBeat Ratings highlights that Novo is betting on pipeline scale, including more than five drugs it sees as having multi blockbuster potential by 2030, plus over $23 billion in expected pipeline sales by 2035, and manufacturing capacity to treat 10 times more obesity patients on oral GLP 1s.
Still, the report emphasizes that investors appear to be focusing on Lilly as the winner, citing Lilly’s more than 60% share and outselling Novo Nordisk by more than two to one, alongside a pipeline that includes additional GLP 1 candidates and objectives such as reducing average weight by up to 25%.